Novavax Inc. (NVAX)
Last updated: 2026-10-21 11:58:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Novavax Inc. (NVAX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $11.45, with a market capitalization of $1.78B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.20 to $13.39. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.78B | |
$11.40 | |
$331.68 | |
$3.53 | |
$11.43 | |
21.29K | |
6.03M | |
-- | |
$13.39 | |
$6.20 | |
-- | |
-- |
Novavax Inc. (NVAX) Pre-Market Stock Price
Novavax Inc. (NVAX) is trading at $11.45 in pre-market trading as of 2026-10-21 11:57:00, up 0.13% ($0.02) from the previous close of $11.43
Pre-market trading shows how investors are pricing NVAX before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Novavax Inc. (NVAX) 7-Day Stock Price Change
Over the past seven days, Novavax Inc. (NVAX) moved from $12.66 to $11.45, representing a decline of 9.60% ($1.21).
The stock traded between $10.55 and $13.34 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 7.92 million shares, down versus the previous seven-day period, indicating lower trading activity.
NVAX 52-Week Price Position
Position in Range: 73.0%
NVAX is currently trading at $11.45, placing it 73.0% of the way from its 52-week low of $6.20 to its 52-week high of $13.39. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Novavax Inc. (NVAX)?
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Novavax Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 749 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Novavax Inc. (NVAX) Stock on MEXC
Eligible investors can buy real shares of Novavax Inc. (NVAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Novavax Inc. (NVAX) stock price today?
2.Is NVAX stock going up or down today?
3.What is NVAX pre-market price?
4.What is NVAX after-hours price?
5.Is NVAX stock trading now?
6.Where does NVAX sit relative to its 52-week high and low?
7.What sector is Novavax Inc. in?
8.What is Novavax Inc.'s market capitalization and where is it listed?
9.How is NVAX valued in terms of P/E ratio and EPS?
10.Does Novavax Inc. pay a dividend?
Explore More US Stocks
Search Stocks
NVAX Stock Calculator
Estimate the value between NVAX shares and USD.
NVAX Shares to USD
1.00 NVAX shares = 11.445 USD
Calculations are estimates based on the latest available price and are for reference only.


